We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Residual FDG- PET metabolic activity in metastatic melanoma patients with prolonged response to anti- PD-1 therapy.
- Authors
Kong, Benjamin Y.; Menzies, Alexander M.; Saunders, Catherine A. B.; Liniker, Elizabeth; Ramanujam, Sangeetha; Guminski, Alex; Kefford, Richard F.; Long, Georgina V.; Carlino, Matteo S.
- Abstract
18-Fluorodeoxyglucose positron emission tomography ( FDG- PET) scans were performed on 27 patients with unresectable stage IIIC or IV melanoma after prolonged treatment with anti- PD-1 antibodies to examine the hypothesis that patients with prolonged response to treatment may have metabolically inactive lesions by FDG- PET. Scans were performed at a median of 15.2 months (range 12-29 months) after starting treatment. Overall, 15 of 27 (56%) patients had a positive FDG- PET scan. Eight patients with positive scans underwent biopsy; 5 of 8 (62%) were melanoma and 3 of 8 (38%) were immune cell infiltrates. Of the 12 patients with negative FDG- PET scans, six had residual computerized tomography-visible lesions, five have ceased treatment, and none have recurred with follow-up of 6-10 months. Patients with residual metastases after a prolonged period without progression on anti- PD-1 therapy may have metabolically inactive lesions. Isolated metabolically active lesions in clinically well patients may reveal immune cell infiltrates rather than melanoma.
- Subjects
FLUORODEOXYGLUCOSE F18; POSITRON emission tomography; MELANOMA treatment; THERAPEUTIC use of monoclonal antibodies; PEMBROLIZUMAB; METASTASIS
- Publication
Pigment Cell & Melanoma Research, 2016, Vol 29, Issue 5, p572
- ISSN
1755-1471
- Publication type
Article
- DOI
10.1111/pcmr.12503